Jon Hu
@Jonyuhu
Followers
25
Following
3
Media
1
Statuses
10
Co-founder and CEO @pepper_bio | Biotech nerd @HarvardHBS MBA | @NorthwesternU Undergrad Former @BainAlerts, @TakedaPharma (Shire Pharma)
Joined September 2012
Shared my thoughts on 2024's pharma trends with @PharmaVoice's @MeaganParrish. Despite the challenges ahead there are big opportunities too. More on how March-In rights might impact biotech, and other trends from industry leaders here:
pharmavoice.com
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
At #JPM2024, our CEO @jonyuhu shared with @PharmaVoice's @MeaganParrish his perspective on what policies will shape biotech in 2024. '"It's not the first time we've heard of march-in rights, but [they] are more mainstream now,' he says. More here:
0
0
0
Join us in giving a warm welcome to Dr. Martin Alexander Gershon, @endeavorfunds, who is starting his role as our senior strategic advisor. Read about his role with @pepper_bio here: https://t.co/SDdxRn6eOC
#transomics #drugdiscovery
biopharmadive.com
0
0
2
How are startups already using AI to transform the way we approach drug discovery? More on this in @WSJ via my conversation with @BrianPGormley and @SamanthaDStrass. https://t.co/dqQgz7vLpR
0
0
0
My op-ed in @statnews explores how patient advocacy groups influence FDA approvals for drugs that don’t have robust clinical data proving impact. Here’s why that's a problem & how I think we can positively redirect patient advocacy for better outcomes:
statnews.com
The current state of patient advocacy needs reform so that the best, safest drugs come to market, writes Jon Hu of Pepper Bio.
1
2
9
Investors like @Merck + @NFX helped us further understand the need for solutions like Pepper Bio in the pharma space. Samantha & I spoke with @RebeccaTorrenc5 from @BusinessInsider, who covers the pitch deck that led to our seed funding. Check it out here:
businessinsider.com
Pepper Bio wants to improve drug discovery for pharma companies using AI. The startup raised a $6.5 million seed round in November.
0
0
0
With our $6.5M seed funding, @PepperBio isn't just advancing drug development; we're accelerating discoveries to put an end to untreatable diseases. Learn more about the funding of our transomics analysis platform via @abracarioca’s latest in @TechCrunch.
techcrunch.com
The biotech startup's $6.5 million seed round is led by VC firm NFX but it is perhaps equally noteworthy to see that Merck is also participating in the round.
0
0
4
Transomics has the ability to find ways to circumvent drug resistance in diseases like non-small cell lung cancer. Read about our research findings as @Pepper_Bio heads to @AACR in Boston: https://t.co/CcXq5bzWJJ
@theNCI @EORTC
0
0
0